Company moves seamlessly from finalization of the SAPHIR Phase 2a to next clinical stage Probiodrug takes a double-pronged strategy – starts operational preparation of clinical studies […]
HALLE (SAALE), Germany, 28 September 2017 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that the company […]
PQ912 delivers positive pharmacodynamic and efficacy results in a Phase-2a study in early stage AD patients Successful settlement of longpending tax issue PQ912 demonstrates efficacy in […]
HALLE (SAALE), Germany, 30 August 2017 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that the company […]
Probiodrug publishes mechanism of target binding for its lead anti-pGlu-Abeta monoclonal antibody PBD-C06 HALLE (SAALE), Germany, 29 August 2017 – Probiodrug AG (Euronext Amsterdam: PBD), […]
HALLE (SAALE), Germany, 24 August 2017 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), will publish its results […]
All proposed resolutions approved with large majority HALLE (SAALE), Germany, 14 June 2017 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions […]
HALLE (SAALE), Germany, 11 June 2017 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), today announced […]
HALLE (SAALE), Germany, 30 May 2017 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that the company […]